Abstract
Oncogenic ras-p21 directly activates jun-N-terminal kinase (JNK) and its substrate, jun as a unique step on its mitogenic signal transduction pathway. This activation is blocked by the specific JNK-jun inhibitor, glutathione-S-transferase-pi (GST-pi). Four domains of GST-pi have been implicated in this regulatory function: 34–50, 99–121, 165–182, and 194–201. The 34–50 domain is unique in that it does not affect GST-pi binding to JNK-jun but blocks jun phosphorylation by JNK. We now find that it completely blocks oncogenic (Val 12-) ras-p21–induced oocyte maturation but has no effect on insulin-induced oocyte maturation. Because the latter process requires activation of wild-type ras-p21, this peptide appears to be specific for inhibiting only the oncogenic form of ras-p21, suggesting its use in treating ras-induced tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adler, V. and Pincus, M. R. (2003) Ann. Clin. Lab. Sci. 34: 35–46.
Adler, V., Pincus, M. R., Brandt-Rauf, P. W., and Ronai, Z. (1995). Proc. Natl. Acad. Sci. U. S. A. 92: 10585–10589.
Adler, V., Pincus, M. R., Polotskaya, A., Montano, X., Friedman, F., and Ronai, Z. (1996). J. Biol. Chem. 271: 23304–23309.
Adler, V., Yin, Z., Fuchs, S., Benezra, M., Rosario, L., Tew, K., et al. (1999). EMBO J. 18: 1321–1334.
Amar, S., Glozman, A., Chung, D. L., Alder, V., Ronai, Z., Friedman, F., et al. (1997). Cancer Chemother. Pharmacol. 41: 79–85.
Barbacid, M. (1987). Ann. Rev. Biochem. 56: 779–827.
Birchmeier, C., Broek, D., and Wigler, M. (1985). Cell 43: 615–621.
Deshpande, A. K. and Kung, H-F. (1987). Mol. Cell. Biol. 7: 1285–1288.
Chie, L., Friedman, F. K., Duncan, T., Chen, J. M., Chung, D. L., and Pincus, M. R. (2004) Protein J. 23: 229–234.
Flatgaard, J. E., Bauer, K. E., and Kauvar, K. M. (1993). Cancer Chemother. Pharmacol. 33: 63–70.
Kanovsky, M., Michl, J., Botzolaki, G., Morin, J., Kovac, C., Chung, D. L., et al. (2003). Cancer Chemother. Pharmacol. 52: 202–208.
Karin, M. (1995). J. Biol. Chem. 270: 16483–16486.
Miura, K., Inouye, Y., Nakamori, H., Iwai, S., Ohtsuka, E., Ikehara, M., et al. (1986). Jpn. J. Cancer Res. (Gann) 77: 45–51.
Monaco, R., Friedman, F. K., Hyde, M. J., Chen, J. M., Manolatus, S., Adler, V., et al. (2000). J. Protein Chem. 18: 859–866.
Pincus, M. R., Brandt-Rauf, P. W., Michl, J., and Friedman, F. K. (2000). Cancer Invest. 46: 35–53.
Pincus, M. R., Brandt-Rauf, P. W., Koslosky, W., and Appruzzese (2001) In: Henry, J. B. (ed.), Clinical Diagnosis and Management by Laboratory Methods, Nineteenth Edition, W. B. Saunders, Philadelphia, pp. 1344–1354.
Ranginwale, M., Smith, S., Flom, J., Chie, L., Kanovsky, M., Chung, D., et al. (2001). Exp. Cell Res. 269: 162–169.
Villafania, A., Anwar, K., Amar, S., Chung, D., Adler, V., Ronai, Z., et al. (1999). Ann. Clin. Lab. Sci. 30: 61–68.
Rights and permissions
About this article
Cite this article
Chie, L., Adler, V., Friedman, F.K. et al. An Effector Peptide from Glutathione-S-Transferase-pi Strongly and Selectively Blocks Mitotic Signaling by Oncogenic ras-p21. J Protein Chem 23, 235–238 (2004). https://doi.org/10.1023/B:JOPC.0000026419.54902.bb
Issue Date:
DOI: https://doi.org/10.1023/B:JOPC.0000026419.54902.bb